The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.
Abstract
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
References1. Selden MA, Helzberg JH, Waeckerle JF, et al. Elevated alanine aminotransferase in current national football league players: correlation with cardiometabolic syndrome markers, obesity, and insulin resistance. South Med J 2009;102:1003–1006.SeldenMA]]HelzbergJH]]WaeckerleJF&etal;Elevated alanine aminotransferase in current national football league players: correlation with cardiometabolic syndrome markers, obesity, and insulin resistance.South Med J20091021003-10062. Bell DS, Allbright E. The multifaceted associations of hepatobiliary disease and diabetes. Endocr Pract 2007;13:300–312.BellDS]]AllbrightEThe multifaceted associations of hepatobiliary disease and diabetes.Endocr Pract200713300-3123. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297–2307.BelfortR]]HarrisonSA]]BrownK&etal;A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.N Engl J Med20063552297-23074. Schneider HJ, Glaesmer H, Klotsche J, et al; DETECT Study Group. Accuracy of anthropometric indicators of obesity to predict cardiovascular risk. J Clin Endocrinol Metab 2007;92:589–594.SchneiderHJ]]GlaesmerH]]KlotscheJ&etal;DETECT Study GroupAccuracy of anthropometric indicators of obesity to predict cardiovascular risk.J Clin Endocrinol Metab200792589-5945. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139:802–809.McLaughlinT]]AbbasiF]]ChealK&etal;Use of metabolic markers to identify overweight individuals who are insulin resistant.Ann Intern Med2003139802-8096. Bell DS. Diabetes: a cardiac condition manifesting as hyperglycemia. Endocr Pract 2008;14:924–932.BellDSDiabetes: a cardiac condition manifesting as hyperglycemia.Endocr Pract200814924-9327. Bell DS. Hypertension and diabetes: a toxic combination. Endocr Pract 2008;14:1031–1039.BellDSHypertension and diabetes: a toxic combination.Endocr Pract2008141031-10398. Nissen SE, Nicholls SJ, Wolski K, et al; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561–1573.NissenSE]]NichollsSJ]]WolskiK&etal;PERISCOPE InvestigatorsComparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.JAMA20082991561-15739. Dormandy JA, Charbonnel B, Eckland DJ, et al; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279–1289.DormandyJA]]CharbonnelB]]EcklandDJ&etal;PROactive InvestigatorsSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.Lancet20053661279-1289
